Immuneering Director Acquires 7.5% More Stock [Yahoo! Finance]
Immuneering Corporation - Class A (IMRX)
Company Research
Source: Yahoo! Finance
Although the purchase only increased their holding by 7.5%, it is still a solid purchase in our view. Check out our latest analysis for Immuneering The Last 12 Months Of Insider Transactions At Immuneering Notably, that recent purchase by Peter Feinberg is the biggest insider purchase of Immuneering shares that we've seen in the last year. So it's clear an insider wanted to buy, even at a higher price than the current share price (being US$2.78). Their view may have changed since then, but at least it shows they felt optimistic at the time. To us, it's very important to consider the price insiders pay for shares. Generally speaking, it catches our eye when insiders have purchased shares at above current prices, as it suggests they believed the shares were worth buying, even at a higher price. In the last twelve months Immuneering insiders were buying shares, but not selling. The average buy price was around US$2.37. It is certainly positive to see that insiders have invested t
Show less
Read more
Impact Snapshot
Event Time:
IMRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMRX alerts
High impacting Immuneering Corporation - Class A news events
Weekly update
A roundup of the hottest topics
IMRX
News
- Immuneering Co. (NASDAQ: IMRX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $15.00 price target on the stock.MarketBeat
- IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models [Yahoo! Finance]Yahoo! Finance
- IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer ModelsGlobeNewswire
- Immuneering to Participate in the 23rd Annual Needham Virtual Healthcare ConferenceGlobeNewswire
- Immuneering Co. (NASDAQ: IMRX) had its price target lowered by analysts at Mizuho from $20.00 to $8.00. They now have a "buy" rating on the stock.MarketBeat
IMRX
Earnings
- 3/1/24 - Miss
IMRX
Sec Filings
- 4/23/24 - Form DEFA14A
- 4/23/24 - Form DEF
- 4/15/24 - Form SC
- IMRX's page on the SEC website